- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Precision Oncology With the Syapse Precision Medicine Council
In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council.
In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council. The council consists of oncology, operations, and research leaders from health systems dedicated to advancing precision medicine through sharing strategies and insights in order to identify best practices.
Dennis Shin, chief commercial officer of Syapse, discussed the formation of the council, how it plans to disrupt the current precision oncology landscape, and what he sees for the future of the council.
To listen, login to the website.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss?rel=0"
TuneIn: http://bit.ly/2gv7iwj?rel=0"
Stitcher: http://bit.ly/2gCqtFg?rel=0"
Syapse, Roche Team Up to Advance Precision Medicine in Oncology
Syapse Looks to Expand Precision Medicine Partnerships With New CEO
Oncologists Are Crucial to Advancing Precision Medicine
Precision Health AI Launches Platform to Deliver Data-Driven Insights in Oncology
Using Health IT to Increase Medication Adherence and Enhance Precision Medicine
Read more about Syapse and precision oncology:
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
